{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T00:58:53Z","timestamp":1792112333730,"version":"4.4.0"},"reference-count":185,"publisher":"Impact Journals, LLC","issue":"39","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,9,27]]},"DOI":"10.18632\/oncotarget.10901","type":"journal-article","created":{"date-parts":[[2016,7,28]],"date-time":"2016-07-28T22:33:57Z","timestamp":1469745237000},"page":"64447-64470","source":"Crossref","is-referenced-by-count":159,"title":["Molecular mechanisms underlying resistance to androgen deprivation therapy in prostate cancer"],"prefix":"10.18632","volume":"7","author":[{"given":"Kristine M.","family":"Wadosky","sequence":"first","affiliation":[{"name":"Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahriar","family":"Koochekpour","sequence":"additional","affiliation":[{"name":"Department of Cancer Genetics, Center for Genetics and Pharmacology, Roswell Park Cancer Institute, Buffalo, NY, USA"},{"name":"Department of Urology, Roswell Park Cancer Institute, Buffalo, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,7,28]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1016\/j.eururo.2012.02.054","article-title":"International variation in prostate cancer incidence and mortality rates","volume":"61","author":"Bray","year":"2012","journal-title":"Eur Urol"},{"key":"2","volume-title":"Cancer Facts & Figures 2015","author":"Society AC","year":"2015"},{"key":"3","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/j.ejca.2012.12.027","article-title":"Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012","volume":"49","author":"Bray","year":"2013","journal-title":"Eur J Cancer"},{"key":"4","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S0022-5347(17)35233-3","article-title":"Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men","volume":"151","author":"Dalkin","year":"1994","journal-title":"J Urol"},{"key":"5","doi-asserted-by":"publisher","first-page":"120","DOI":"10.7326\/0003-4819-157-2-201207170-00459","article-title":"Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement","volume":"157","author":"Force","year":"2012","journal-title":"Ann Intern Med"},{"key":"6","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.juro.2013.04.119","article-title":"Early detection of prostate cancer: AUA Guideline","volume":"190","author":"Zietman","year":"2013","journal-title":"J Urol"},{"key":"7","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.eururo.2013.09.046","article-title":"EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update","volume":"65","author":"European Association of","year":"2013","journal-title":"Eur Urol"},{"key":"8","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1007\/s11934-014-0420-7","article-title":"Implications of the new AUA guidelines on prostate cancer detection in the U.S","volume":"15","author":"Cooperberg","year":"2014","journal-title":"Curr Urol Rep"},{"key":"9","doi-asserted-by":"publisher","first-page":"2581","DOI":"10.1200\/JCO.2011.40.4327","article-title":"Prostate cancer screening: facts, statistics, and interpretation in response to the US Preventive Services Task Force Review","volume":"30","author":"Hugosson","year":"2012","journal-title":"J Clin Oncol"},{"key":"10","doi-asserted-by":"publisher","first-page":"c4543","DOI":"10.1136\/bmj.c4543","article-title":"Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials","volume":"341","author":"Dahm","year":"2010","journal-title":"BMJ"},{"key":"11","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1111\/j.1464-410X.2010.10032.x","article-title":"Screening for prostate cancer: an updated Cochrane systematic review","volume":"107","author":"Wilt","year":"2011","journal-title":"BJU Int"},{"key":"12","first-page":"5875","article-title":"Screening for prostate cancer: the current evidence and guidelines controversy","volume":"18","author":"Wender","year":"2011","journal-title":"Can J Urol"},{"key":"13","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1038\/nrurol.2015.242","article-title":"Imaging and evaluation of patients with high-risk prostate cancer","volume":"12","author":"Taneja","year":"2015","journal-title":"Nat Rev Urol"},{"key":"14","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1038\/nrurol.2015.191","article-title":"Initial prostate cancer diagnosis and disease staging--the role of choline-PET-CT","volume":"12","author":"Picchio","year":"2015","journal-title":"Nat Rev Urol"},{"key":"15","first-page":"125","article-title":"Classification of prostatic carcinomas","volume":"50","author":"Gleason","year":"1966","journal-title":"Cancer Chemother Rep"},{"key":"16","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/S0022-5347(17)59889-4","article-title":"Prediction of prognosis for prostatic adenocarcinoma by combined histological grading and clinical staging","volume":"111","author":"Mellinger","year":"1974","journal-title":"J Urol"},{"key":"17","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/modpathol.3800054","article-title":"Gleason grading and prognostic factors in carcinoma of the prostate","volume":"17","author":"Humphrey","year":"2004","journal-title":"Mod Pathol"},{"key":"18","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1016\/j.juro.2009.10.046","article-title":"An update of the Gleason grading system","volume":"183","author":"Epstein","year":"2010","journal-title":"J Urol"},{"key":"19","doi-asserted-by":"publisher","DOI":"10.1002\/pros.23142","article-title":"Changes in prostate cancer grading: Including a new patient-centric grading system","author":"Epstein","year":"2015","journal-title":"Prostate"},{"key":"20","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000530","article-title":"The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System","author":"Humphrey","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"21","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.semradonc.2013.01.002","article-title":"Prognostic factors for newly diagnosed prostate cancer and their role in treatment selection","volume":"23","author":"Ots","year":"2013","journal-title":"Semin Radiat Oncol"},{"key":"22","unstructured":"2010. AJCC Cancer Staging Manual. Springer-Verlag, New York."},{"key":"23","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.280.11.969","article-title":"Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer","volume":"280","author":"Wein","year":"1998","journal-title":"JAMA"},{"key":"24","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1200\/JCO.2009.26.0133","article-title":"Time trends and local variation in primary treatment of localized prostate cancer","volume":"28","author":"Carroll","year":"2010","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1016\/j.urology.2007.03.042","article-title":"Updated nomogram to predict pathologic stage of prostate cancer given prostate-specific antigen level, clinical stage, and biopsy Gleason score (Partin tables) based on cases from 2000 to 2005","volume":"69","author":"Partin","year":"2007","journal-title":"Urology"},{"key":"26","doi-asserted-by":"crossref","first-page":"162","DOI":"10.6004\/jnccn.2010.0012","article-title":"NCCN clinical practice guidelines in oncology: prostate cancer","volume":"8","author":"Kuettel","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"27","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1016\/j.eururo.2012.02.031","article-title":"High-risk prostate cancer: from definition to contemporary management","volume":"61","author":"Zelefsky","year":"2012","journal-title":"Eur Urol"},{"key":"28","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1093\/jnci\/djp122","article-title":"Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis","volume":"101","author":"Carroll","year":"2009","journal-title":"J Natl Cancer Inst"},{"key":"29","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1016\/j.juro.2007.03.003","article-title":"Guideline for the management of clinically localized prostate cancer: 2007 update","volume":"177","author":"Higano","year":"2007","journal-title":"J Urol"},{"issue":"Suppl 1","key":"30","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1016\/j.critrevonc.2012.12.002","article-title":"How to select the optimal therapy for early-stage prostate cancer","volume":"84","author":"Zelefsky","year":"2012","journal-title":"Crit Rev Oncol Hematol"},{"key":"31","doi-asserted-by":"publisher","DOI":"10.1111\/iju.13016","article-title":"Active surveillance for prostate cancer","author":"Touijer","year":"2015","journal-title":"Int J Urol"},{"key":"32","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1056\/NEJMoa1201637","article-title":"Quality-of-life effects of prostate-specific antigen screening","volume":"367","author":"Makinen","year":"2012","journal-title":"N Engl J Med"},{"key":"33","doi-asserted-by":"publisher","first-page":"409","DOI":"10.7150\/ijbs.14090","article-title":"Therapeutic Rationales, Progresses, Failures, and Future Directions for Advanced Prostate Cancer","volume":"12","author":"Koochekpour","year":"2016","journal-title":"Int J Biol Sci"},{"key":"34","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.clon.2014.11.004","article-title":"Primary radical therapy selection in high-risk non-metastatic prostate cancer","volume":"27","author":"Johnstone","year":"2015","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"35","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.eururo.2007.10.009","article-title":"An analysis of radical prostatectomy in advanced stage and high-grade prostate cancer","volume":"53","author":"Joniau","year":"2008","journal-title":"Eur Urol"},{"key":"36","doi-asserted-by":"publisher","first-page":"888","DOI":"10.4103\/1008-682X.156855","article-title":"Optimal management of prostate cancer with lethal biology - state-of-the-art local therapy","volume":"17","author":"Chapin","year":"2015","journal-title":"Asian J Androl"},{"key":"37","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.eururo.2013.11.002","article-title":"EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"European Association of","year":"2014","journal-title":"Eur Urol"},{"key":"38","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/ncpuro1296","article-title":"Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion","volume":"6","author":"Montgomery","year":"2009","journal-title":"Nat Clin Pract Urol"},{"key":"39","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","author":"Jones","year":"2015","journal-title":"Lancet"},{"key":"40","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","author":"Sydes","year":"2015","journal-title":"Lancet Oncol"},{"key":"41","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer","author":"Picus","year":"2015","journal-title":"N Engl J Med"},{"key":"42","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1016\/j.eururo.2014.07.010","article-title":"Adverse effects of androgen deprivation therapy and strategies to mitigate them","volume":"67","author":"Smith","year":"2015","journal-title":"Eur Urol"},{"key":"43","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MOU.0000000000000101","article-title":"Androgen-deprivation-associated bone disease","volume":"24","author":"Shahinian","year":"2014","journal-title":"Curr Opin Urol"},{"key":"44","doi-asserted-by":"publisher","first-page":"R371","DOI":"10.1530\/ERC-14-0172","article-title":"Muscle and bone effects of androgen deprivation therapy: current and emerging therapies","volume":"21","author":"Grossmann","year":"2014","journal-title":"Endocr Relat Cancer"},{"key":"45","doi-asserted-by":"publisher","first-page":"3271","DOI":"10.1200\/JCO.2011.38.8850","article-title":"Sarcopenia during androgen-deprivation therapy for prostate cancer","volume":"30","author":"Goessl","year":"2012","journal-title":"J Clin Oncol"},{"key":"46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1016\/j.clgc.2014.07.009","article-title":"The effects of androgen deprivation therapy on cardiac function and heart failure: implications for management of prostate cancer","volume":"12","author":"Khan","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"47","doi-asserted-by":"publisher","first-page":"194","DOI":"10.3322\/caac.20061","article-title":"Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology","volume":"60","author":"Zakai","year":"2010","journal-title":"CA Cancer J Clin"},{"key":"48","doi-asserted-by":"publisher","first-page":"2420","DOI":"10.1200\/JCO.2006.09.3369","article-title":"Influence of androgen suppression therapy for prostate cancer on the frequency and timing of fatal myocardial infarctions","volume":"25","author":"Kantoff","year":"2007","journal-title":"J Clin Oncol"},{"key":"49","doi-asserted-by":"publisher","DOI":"10.1111\/bju.12905","article-title":"Association of androgen-deprivation therapy with excess cardiac-specific mortality in men with prostate cancer","author":"Hoffman","year":"2014","journal-title":"BJU Int"},{"key":"50","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Paszat","year":"2009","journal-title":"J Clin Oncol"},{"key":"51","doi-asserted-by":"publisher","DOI":"10.1111\/andr.12141","article-title":"No increased risk of coronary heart disease for patients receiving androgen deprivation therapy for prostate cancer in Chinese\/Taiwanese men","author":"Huang","year":"2015","journal-title":"Andrology"},{"key":"52","doi-asserted-by":"publisher","first-page":"S34","DOI":"10.1016\/j.juro.2012.11.017","article-title":"Metabolic complications of androgen deprivation therapy for prostate cancer","volume":"189","author":"Smith","year":"2013","journal-title":"J Urol"},{"key":"53","doi-asserted-by":"crossref","first-page":"41","DOI":"10.3816\/CGC.2003.n.011","article-title":"Ten-year survival in patients with metastatic prostate cancer","volume":"2","author":"Hussain","year":"2003","journal-title":"Clin Prostate Cancer"},{"key":"54","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Basch","year":"2008","journal-title":"J Clin Oncol"},{"key":"55","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1038\/nrc4016","article-title":"Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer","volume":"15","author":"Sawyers","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"56","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer","volume":"364","author":"Harland","year":"2011","journal-title":"N Engl J Med"},{"key":"57","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Basch","year":"2013","journal-title":"N Engl J Med"},{"key":"58","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Evans","year":"2014","journal-title":"N Engl J Med"},{"key":"59","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Flechon","year":"2012","journal-title":"N Engl J Med"},{"key":"60","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Investigators","year":"2004","journal-title":"N Engl J Med"},{"key":"61","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa041318","article-title":"Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer","volume":"351","author":"Raghavan","year":"2004","journal-title":"N Engl J Med"},{"key":"62","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Tannock","year":"2008","journal-title":"J Clin Oncol"},{"key":"63","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"Sartor","year":"2010","journal-title":"Lancet"},{"key":"64","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1517\/14656566.2014.915313","article-title":"Targeting the androgen receptor in prostate cancer","volume":"15","author":"Culig","year":"2014","journal-title":"Expert Opin Pharmacother"},{"key":"65","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.254","article-title":"Androgen-glucocorticoid interactions in the era of novel prostate cancer therapy","author":"Feldman","year":"2015","journal-title":"Nat Rev Urol"},{"key":"66","doi-asserted-by":"publisher","first-page":"2815","DOI":"10.1038\/onc.2014.238","article-title":"DNA damage response and prostate cancer: defects, regulation and therapeutic implications","volume":"34","author":"Thompson","year":"2015","journal-title":"Oncogene"},{"key":"67","doi-asserted-by":"publisher","first-page":"7121","DOI":"10.1158\/1078-0432.CCR-04-0913","article-title":"The influence of androgen deprivation therapy on dihydrotestosterone levels in the prostatic tissue of patients with prostate cancer","volume":"10","author":"Takahashi","year":"2004","journal-title":"Clin Cancer Res"},{"key":"68","doi-asserted-by":"publisher","first-page":"4653","DOI":"10.1158\/1078-0432.CCR-05-0525","article-title":"Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer","volume":"11","author":"Mohler","year":"2005","journal-title":"Clin Cancer Res"},{"key":"69","doi-asserted-by":"publisher","first-page":"4447","DOI":"10.1158\/0008-5472.CAN-08-0249","article-title":"Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth","volume":"68","author":"Nelson","year":"2008","journal-title":"Cancer Res"},{"key":"70","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1038\/sj.bjc.6690684","article-title":"Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system","volume":"81","author":"Klocker","year":"1999","journal-title":"Br J Cancer"},{"key":"71","first-page":"2892","article-title":"Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen","volume":"61","author":"Wilson","year":"2001","journal-title":"Cancer Res"},{"key":"72","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrurol.2013.274","article-title":"CYP17 inhibitors--abiraterone, C17,20-lyase inhibitors and multi-targeting agents","volume":"11","author":"Hu","year":"2014","journal-title":"Nat Rev Urol"},{"key":"73","doi-asserted-by":"publisher","first-page":"596","DOI":"10.7150\/ijbs.8780","article-title":"Roles for the backdoor pathway of androgen metabolism in prostate cancer response to castration and drug treatment","volume":"10","author":"Mohler","year":"2014","journal-title":"Int J Biol Sci"},{"key":"74","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.cbi.2014.12.012","article-title":"The DHEA-sulfate depot following P450c17 inhibition supports the case for AKR1C3 inhibition in high risk localized and advanced castration resistant prostate cancer","volume":"234","author":"Penning","year":"2015","journal-title":"Chem Biol Interact"},{"key":"75","doi-asserted-by":"publisher","first-page":"14","DOI":"10.3109\/1061186X.2013.832767","article-title":"Organic anion-transporting polypeptides: a novel approach for cancer therapy","volume":"22","author":"Li","year":"2014","journal-title":"J Drug Target"},{"key":"76","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1016\/j.bcp.2012.07.026","article-title":"Enhanced expression of organic anion transporting polypeptides (OATPs) in androgen receptor-positive prostate cancer cells: possible role of OATP1A2 in adaptive cell growth under androgen-depleted conditions","volume":"84","author":"Tamai","year":"2012","journal-title":"Biochem Pharmacol"},{"key":"77","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1006\/frne.2001.0216","article-title":"DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology","volume":"22","author":"Simard","year":"2001","journal-title":"Front Neuroendocrinol"},{"key":"78","doi-asserted-by":"publisher","first-page":"6503","DOI":"10.1158\/0008-5472.CAN-11-0532","article-title":"Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors","volume":"71","author":"Balk","year":"2011","journal-title":"Cancer Res"},{"key":"79","doi-asserted-by":"publisher","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Nelson","year":"2008","journal-title":"Cancer Res"},{"key":"80","doi-asserted-by":"publisher","first-page":"5547","DOI":"10.1158\/1078-0432.CCR-13-3483","article-title":"Canonical androstenedione reduction is the predominant source of signaling androgens in hormone-refractory prostate cancer","volume":"20","author":"Corcoran","year":"2014","journal-title":"Clin Cancer Res"},{"key":"81","doi-asserted-by":"publisher","first-page":"2628","DOI":"10.1002\/cncr.28675","article-title":"Concept and viability of androgen annihilation for advanced prostate cancer","volume":"120","author":"Mohler","year":"2014","journal-title":"Cancer"},{"key":"82","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.mce.2008.08.013","article-title":"Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol","volume":"295","author":"Khan","year":"2008","journal-title":"Mol Cell Endocrinol"},{"key":"83","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1002\/pros.21072","article-title":"Alterations in cholesterol regulation contribute to the production of intratumoral androgens during progression to castration-resistant prostate cancer in a mouse xenograft model","volume":"70","author":"Wasan","year":"2010","journal-title":"Prostate"},{"key":"84","doi-asserted-by":"publisher","first-page":"35542","DOI":"10.18632\/oncotarget.4689","article-title":"Adaptive responses of androgen receptor signaling in castration-resistant prostate cancer","volume":"6","author":"Baniahmad","year":"2015","journal-title":"Oncotarget"},{"key":"85","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1126\/science.3353726","article-title":"Molecular cloning of human and rat complementary DNA encoding androgen receptors","volume":"240","author":"Liao","year":"1988","journal-title":"Science"},{"key":"86","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1126\/science.3353727","article-title":"Cloning of human androgen receptor complementary DNA and localization to the X chromosome","volume":"240","author":"Wilson","year":"1988","journal-title":"Science"},{"key":"87","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1038\/ng0495-401","article-title":"In vivo amplification of the androgen receptor gene and progression of human prostate cancer","volume":"9","author":"Kallioniemi","year":"1995","journal-title":"Nat Genet"},{"key":"88","first-page":"803","article-title":"Survey of gene amplifications during prostate cancer progression by high-throughout fluorescence in situ hybridization on tissue microarrays","volume":"59","author":"Kallioniemi","year":"1999","journal-title":"Cancer Res"},{"key":"89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1002\/(SICI)1097-0045(20000515)43:3<225::AID-PROS9>3.0.CO;2-7","article-title":"Fluorescence in situ hybridization evaluation of c-myc and androgen receptor gene amplification and chromosomal anomalies in prostate cancer in Japanese patients","volume":"43","author":"Kubota","year":"2000","journal-title":"Prostate"},{"key":"90","first-page":"3550","article-title":"Amplification and overexpression of androgen receptor gene in hormone-refractory prostate cancer","volume":"61","author":"Visakorpi","year":"2001","journal-title":"Cancer Res"},{"key":"91","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/nm972","article-title":"Molecular determinants of resistance to antiandrogen therapy","volume":"10","author":"Sawyers","year":"2004","journal-title":"Nat Med"},{"key":"92","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/S0002-9440(10)64365-9","article-title":"Androgen receptor expression and cellular proliferation during transition from androgen-dependent to recurrent growth after castration in the CWR22 prostate cancer xenograft","volume":"160","author":"Mohler","year":"2002","journal-title":"Am J Pathol"},{"key":"93","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2015.08.005","article-title":"Therapy escape mechanisms in the malignant prostate","author":"McNeill","year":"2015","journal-title":"Semin Cancer Biol"},{"key":"94","doi-asserted-by":"publisher","first-page":"14833","DOI":"10.3390\/ijms140714833","article-title":"Posttranslational modification of the androgen receptor in prostate cancer","volume":"14","author":"Huang","year":"2013","journal-title":"Int J Mol Sci"},{"key":"95","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/nrurol.2014.320","article-title":"Targeting heat shock proteins in metastatic castration-resistant prostate cancer","volume":"12","author":"Chi","year":"2015","journal-title":"Nat Rev Urol"},{"key":"96","doi-asserted-by":"publisher","first-page":"32641","DOI":"10.1074\/jbc.M113.485912","article-title":"Deubiquitinating enzyme Usp12 is a novel co-activator of the androgen receptor","volume":"288","author":"Robson","year":"2013","journal-title":"J Biol Chem"},{"key":"97","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1016\/j.celrep.2014.01.013","article-title":"Destruction of full-length androgen receptor by wild-type SPOP, but not prostate-cancer-associated mutants","volume":"6","author":"Huang","year":"2014","journal-title":"Cell Rep"},{"key":"98","doi-asserted-by":"publisher","first-page":"1754","DOI":"10.18632\/oncotarget.6434","article-title":"Protein phosphatase 1 suppresses androgen receptor ubiquitylation and degradation","volume":"7","author":"Chen","year":"2016","journal-title":"Oncotarget"},{"key":"99","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1038\/onc.2012.561","article-title":"Androgen receptor degradation by the E3 ligase CHIP modulates mitotic arrest in prostate cancer cells","volume":"33","author":"Larner","year":"2014","journal-title":"Oncogene"},{"key":"100","doi-asserted-by":"publisher","first-page":"8141","DOI":"10.1158\/0008-5472.CAN-09-0919","article-title":"Increased expression of androgen receptor sensitizes prostate cancer cells to low levels of androgens","volume":"69","author":"Visakorpi","year":"2009","journal-title":"Cancer Res"},{"key":"101","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1002\/cncr.23473","article-title":"Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426)","volume":"112","author":"Southwest Oncology","year":"2008","journal-title":"Cancer"},{"key":"102","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0006-291X(05)80067-1","article-title":"A mutation in the ligand binding domain of the androgen receptor of human LNCaP cells affects steroid binding characteristics and response to anti-androgens","volume":"173","author":"Mulder","year":"1990","journal-title":"Biochem Biophys Res Commun"},{"key":"103","first-page":"1809","article-title":"LNCaP model of human prostatic carcinoma","volume":"43","author":"Murphy","year":"1983","journal-title":"Cancer Res"},{"key":"104","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1210\/mend.11.4.9906","article-title":"Dehydroepiandrosterone activates mutant androgen receptors expressed in the androgen-dependent human prostate cancer xenograft CWR22 and LNCaP cells","volume":"11","author":"French","year":"1997","journal-title":"Mol Endocrinol"},{"key":"105","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1038\/aja.2010.89","article-title":"Androgen receptor signaling and mutations in prostate cancer","volume":"12","author":"Koochekpour","year":"2010","journal-title":"Asian J Androl"},{"key":"106","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/1097-0045(199609)29:3<153::AID-PROS2990290303>3.0.CO;2-5","article-title":"Codon 877 mutation in the androgen receptor gene in advanced prostate cancer: relation to antiandrogen withdrawal syndrome","volume":"29","author":"Shimazaki","year":"1996","journal-title":"Prostate"},{"key":"107","doi-asserted-by":"crossref","first-page":"2192","DOI":"10.1016\/S0022-5347(05)68158-X","article-title":"Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a","volume":"162","author":"Feldman","year":"1999","journal-title":"J Urol"},{"key":"108","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1002\/ijc.2910570319","article-title":"Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells","volume":"57","author":"Chung","year":"1994","journal-title":"Int J Cancer"},{"key":"109","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1002\/1097-0045(20000701)44:2<91::AID-PROS1>3.0.CO;2-L","article-title":"LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis","volume":"44","author":"Chung","year":"2000","journal-title":"Prostate"},{"key":"110","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/0960-0760(93)90316-O","article-title":"Androgen receptor gene mutations in human prostate cancer","volume":"46","author":"Shimazaki","year":"1993","journal-title":"J Steroid Biochem Mol Biol"},{"key":"111","first-page":"2861","article-title":"Frequent detection of codon 877 mutation in the androgen receptor gene in advanced prostate cancers","volume":"54","author":"Srivastava","year":"1994","journal-title":"Cancer Res"},{"key":"112","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/76287","article-title":"Glucocorticoids can promote androgen-independent growth of prostate cancer cells through a mutated androgen receptor","volume":"6","author":"Feldman","year":"2000","journal-title":"Nat Med"},{"key":"113","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/endo.143.5.8778","article-title":"A glucocorticoid-responsive mutant androgen receptor exhibits unique ligand specificity: therapeutic implications for androgen-independent prostate cancer","volume":"143","author":"Feldman","year":"2002","journal-title":"Endocrinology"},{"key":"114","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.eururo.2012.08.053","article-title":"Targeted next-generation sequencing of advanced prostate cancer identifies potential therapeutic targets and disease heterogeneity","volume":"63","author":"Cronin","year":"2013","journal-title":"Eur Urol"},{"key":"115","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1016\/j.cell.2015.05.001","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"161","author":"Bradley","year":"2015","journal-title":"Cell"},{"key":"116","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1158\/1078-0432.CCR-14-2666","article-title":"Androgen Receptor Gene Aberrations in Circulating Cell-Free DNA: Biomarkers of Therapeutic Resistance in Castration-Resistant Prostate Cancer","volume":"21","author":"Thomas","year":"2015","journal-title":"Clin Cancer Res"},{"key":"117","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1530\/JOE-12-0238","article-title":"Regulation of the androgen receptor by post-translational modifications","volume":"215","author":"Robson","year":"2012","journal-title":"J Endocrinol"},{"key":"118","doi-asserted-by":"publisher","first-page":"20989","DOI":"10.1074\/jbc.M802392200","article-title":"Site-specific androgen receptor serine phosphorylation linked to epidermal growth factor-dependent growth of castration-recurrent prostate cancer","volume":"283","author":"Wilson","year":"2008","journal-title":"J Biol Chem"},{"key":"119","doi-asserted-by":"publisher","first-page":"50902","DOI":"10.1074\/jbc.M300676200","article-title":"Suppression versus induction of androgen receptor functions by the phosphatidylinositol 3-kinase\/Akt pathway in prostate cancer LNCaP cells with different passage numbers","volume":"278","author":"Chang","year":"2003","journal-title":"J Biol Chem"},{"key":"120","first-page":"2577","article-title":"Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer","volume":"54","author":"Chung","year":"1994","journal-title":"Cancer Res"},{"key":"121","doi-asserted-by":"publisher","first-page":"33743","DOI":"10.18632\/oncotarget.5608","article-title":"AR-v7 protein expression is regulated by protein kinase and phosphatase","volume":"6","author":"Dong","year":"2015","journal-title":"Oncotarget"},{"key":"122","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1038\/sj.bjc.6604152","article-title":"Phosphorylation of the androgen receptor is associated with reduced survival in hormone-refractory prostate cancer patients","volume":"98","author":"Edwards","year":"2008","journal-title":"Br J Cancer"},{"key":"123","doi-asserted-by":"publisher","first-page":"16656","DOI":"10.3390\/ijms140816656","article-title":"Androgen receptor phosphorylation at serine 308 and serine 791 predicts enhanced survival in castrate resistant prostate cancer patients","volume":"14","author":"Edwards","year":"2013","journal-title":"Int J Mol Sci"},{"key":"124","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1007\/s00018-011-0766-7","article-title":"Androgen receptor and its splice variants in prostate cancer","volume":"68","author":"Sadar","year":"2011","journal-title":"Cell Mol Life Sci"},{"key":"125","doi-asserted-by":"publisher","first-page":"178","DOI":"10.3978\/j.issn.2223-4683.2013.09.08","article-title":"Decoding the androgen receptor splice variants","volume":"2","author":"Luo","year":"2013","journal-title":"Transl Androl Urol"},{"key":"126","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","article-title":"Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance","volume":"68","author":"Tindall","year":"2008","journal-title":"Cancer Res"},{"key":"127","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1158\/0008-5472.CAN-08-2764","article-title":"Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer","volume":"69","author":"Luo","year":"2009","journal-title":"Cancer Res"},{"key":"128","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-08-3795","article-title":"A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth","volume":"69","author":"Edwards","year":"2009","journal-title":"Cancer Res"},{"key":"129","doi-asserted-by":"publisher","first-page":"2715","DOI":"10.1172\/JCI41824","article-title":"Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant","volume":"120","author":"Plymate","year":"2010","journal-title":"J Clin Invest"},{"key":"130","doi-asserted-by":"publisher","first-page":"19736","DOI":"10.1074\/jbc.M112.352930","article-title":"Androgen receptor splice variants activate androgen receptor target genes and support aberrant prostate cancer cell growth independent of canonical androgen receptor nuclear localization signal","volume":"287","author":"Dehm","year":"2012","journal-title":"J Biol Chem"},{"key":"131","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1002\/pros.21382","article-title":"A snapshot of the expression signature of androgen receptor splicing variants and their distinctive transcriptional activities","volume":"71","author":"Luo","year":"2011","journal-title":"Prostate"},{"key":"132","doi-asserted-by":"publisher","first-page":"27440","DOI":"10.18632\/oncotarget.4578","article-title":"Galeterone and VNPT55 induce proteasomal degradation of AR\/AR-V7, induce significant apoptosis via cytochrome c release and suppress growth of castration resistant prostate cancer xenografts in vivo","volume":"6","author":"Njar","year":"2015","journal-title":"Oncotarget"},{"key":"133","doi-asserted-by":"publisher","first-page":"1646","DOI":"10.18632\/oncotarget.1802","article-title":"Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy","volume":"5","author":"Dong","year":"2014","journal-title":"Oncotarget"},{"key":"134","doi-asserted-by":"publisher","first-page":"16759","DOI":"10.1073\/pnas.1012443107","article-title":"Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor","volume":"107","author":"Sawyers","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"135","doi-asserted-by":"publisher","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Luo","year":"2012","journal-title":"Cancer Res"},{"key":"136","doi-asserted-by":"publisher","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","article-title":"Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survival","volume":"6","author":"Wikstrom","year":"2011","journal-title":"PLoS One"},{"key":"137","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa1315815","article-title":"AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer","volume":"371","author":"De Marzo","year":"2014","journal-title":"N Engl J Med"},{"key":"138","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1038\/sj.bjc.6601879","article-title":"Hormonal impact of the 17alpha-hydroxylase\/C(17,20)-lyase inhibitor abiraterone acetate (CB7630) in patients with prostate cancer","volume":"90","author":"Jarman","year":"2004","journal-title":"Br J Cancer"},{"key":"139","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1200\/JCO.2007.15.9749","article-title":"Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven","volume":"26","author":"Kaye","year":"2008","journal-title":"J Clin Oncol"},{"key":"140","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/0092-8674(95)90199-X","article-title":"The nuclear receptor superfamily: the second decade","volume":"83","author":"Evans","year":"1995","journal-title":"Cell"},{"key":"141","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0303-7207(95)03477-O","article-title":"Quantitative differences in androgen and glucocorticoid receptor DNA binding properties contribute to receptor-selective transcriptional regulation","volume":"109","author":"Miesfeld","year":"1995","journal-title":"Mol Cell Endocrinol"},{"key":"142","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1158\/0008-5472.CAN-12-2350","article-title":"FoxA1 specifies unique androgen and glucocorticoid receptor binding events in prostate cancer cells","volume":"73","author":"Janne","year":"2013","journal-title":"Cancer Res"},{"key":"143","doi-asserted-by":"publisher","first-page":"1309","DOI":"10.1016\/j.cell.2013.11.012","article-title":"Glucocorticoid receptor confers resistance to antiandrogens by bypassing androgen receptor blockade","volume":"155","author":"Sawyers","year":"2013","journal-title":"Cell"},{"key":"144","first-page":"2418","article-title":"Genomic instability of microsatellite repeats in prostate cancer: relationship to clinicopathological variables","volume":"55","author":"Koshiba","year":"1995","journal-title":"Cancer Res"},{"key":"145","first-page":"4475","article-title":"Allelic imbalance and microsatellite instability in prostatic adenocarcinoma","volume":"56","author":"Thibodeau","year":"1996","journal-title":"Cancer Res"},{"key":"146","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1002\/(SICI)1097-0045(19990615)40:1<20::AID-PROS3>3.0.CO;2-4","article-title":"Microsatellite instability and loss of heterozygosity in prostatic carcinomas: comparison of primary tumors, and of corresponding recurrences after androgen-deprivation therapy and lymph-node metastases","volume":"40","author":"Lohrs","year":"1999","journal-title":"Prostate"},{"key":"147","first-page":"4112","article-title":"Defects of DNA mismatch repair in human prostate cancer","volume":"61","author":"Schweinfest","year":"2001","journal-title":"Cancer Res"},{"key":"148","first-page":"1033","article-title":"Alterations in PMS2, MSH2 and MLH1 expression in human prostate cancer","volume":"22","author":"Schweinfest","year":"2003","journal-title":"Int J Oncol"},{"key":"149","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1016\/S0022-5347(05)67115-7","article-title":"The mismatch repair gene hMSH2 is mutated in the prostate cancer cell line LNCaP","volume":"164","author":"McConnell","year":"2000","journal-title":"J Urol"},{"key":"150","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/B978-0-12-407681-5.00002-7","article-title":"Mismatch repair proteins in recurrent prostate cancer","volume":"60","author":"Scarpinato","year":"2013","journal-title":"Adv Clin Chem"},{"key":"151","doi-asserted-by":"publisher","DOI":"10.1038\/nrurol.2015.298","article-title":"Prostate cancer in men of African origin","author":"Moul","year":"2015","journal-title":"Nat Rev Urol"},{"key":"152","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1158\/1078-0432.CCR-12-2795","article-title":"Castration therapy results in decreased Ku70 levels in prostate cancer","volume":"19","author":"Helleday","year":"2013","journal-title":"Clin Cancer Res"},{"key":"153","doi-asserted-by":"crossref","first-page":"8076","DOI":"10.1073\/pnas.94.15.8076","article-title":"Ku70-deficient embryonic stem cells have increased ionizing radiosensitivity, defective DNA end-binding activity, and inability to support V(D)J recombination","volume":"94","author":"Alt","year":"1997","journal-title":"Proc Natl Acad Sci U S A"},{"key":"154","doi-asserted-by":"publisher","first-page":"10827","DOI":"10.1074\/jbc.M413336200","article-title":"Ku is a novel transcriptional recycling coactivator of the androgen receptor in prostate cancer cells","volume":"280","author":"Kung","year":"2005","journal-title":"J Biol Chem"},{"key":"155","first-page":"305","article-title":"Gamma-H2AX - a novel biomarker for DNA double-strand breaks","volume":"22","author":"Yang","year":"2008","journal-title":"In Vivo"},{"key":"156","doi-asserted-by":"publisher","first-page":"312re11","DOI":"10.1126\/scitranslmed.aac5671","article-title":"Castration radiosensitizes prostate cancer tissue by impairing DNA double-strand break repair","volume":"7","author":"Helleday","year":"2015","journal-title":"Sci Transl Med"},{"key":"157","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1158\/2159-8290.CD-13-0172","article-title":"Androgen receptor signaling regulates DNA repair in prostate cancers","volume":"3","author":"Watson","year":"2013","journal-title":"Cancer Discov"},{"key":"158","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.1056\/NEJMoa1506859","article-title":"DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"373","author":"Flohr","year":"2015","journal-title":"N Engl J Med"},{"key":"159","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"160","doi-asserted-by":"publisher","first-page":"6130","DOI":"10.1158\/0008-5472.CAN-07-0533","article-title":"MicroRNA expression profiling in prostate cancer","volume":"67","author":"Visakorpi","year":"2007","journal-title":"Cancer Res"},{"key":"161","doi-asserted-by":"publisher","first-page":"4460","DOI":"10.1038\/onc.2011.624","article-title":"Androgen-regulated miR-32 targets BTG2 and is overexpressed in castration-resistant prostate cancer","volume":"31","author":"Visakorpi","year":"2012","journal-title":"Oncogene"},{"key":"162","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.cancergen.2015.02.010","article-title":"Microdissecting the role of microRNAs in the pathogenesis of prostate cancer","volume":"208","author":"Ayub","year":"2015","journal-title":"Cancer Genet"},{"key":"163","doi-asserted-by":"publisher","DOI":"10.1038\/jhg.2016.69","article-title":"The roles of microRNAs in the progression of castration-resistant prostate cancer","author":"Naya","year":"2016","journal-title":"J Hum Genet"},{"key":"164","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1038\/mt.2009.207","article-title":"Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes","volume":"18","author":"Ochiya","year":"2010","journal-title":"Mol Ther"},{"key":"165","first-page":"432","article-title":"Inactivation of AR and Notch-1 signaling by miR-34a attenuates prostate cancer aggressiveness","volume":"4","author":"Sarkar","year":"2012","journal-title":"Am J Transl Res"},{"key":"166","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1158\/0008-5472.CAN-10-2421","article-title":"Systematic analysis of microRNAs targeting the androgen receptor in prostate cancer cells","volume":"71","author":"Perala","year":"2011","journal-title":"Cancer Res"},{"key":"167","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.bbrc.2008.09.086","article-title":"Effects of miR-34a on cell growth and chemoresistance in prostate cancer PC3 cells","volume":"377","author":"Ito","year":"2008","journal-title":"Biochem Biophys Res Commun"},{"key":"168","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1158\/1078-0432.CCR-12-2952","article-title":"miRNA-34b inhibits prostate cancer through demethylation, active chromatin modifications, and AKT pathways","volume":"19","author":"Dahiya","year":"2013","journal-title":"Clin Cancer Res"},{"key":"169","doi-asserted-by":"publisher","first-page":"e7542","DOI":"10.1371\/journal.pone.0007542","article-title":"miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice","volume":"4","author":"Fajas","year":"2009","journal-title":"PLoS One"},{"key":"170","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1002\/pros.22469","article-title":"Biochemical relapse following radical prostatectomy and miR-200a levels in prostate cancer","volume":"72","author":"Clynes","year":"2012","journal-title":"Prostate"},{"key":"171","doi-asserted-by":"publisher","first-page":"1695","DOI":"10.1126\/science.1165395","article-title":"Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer","volume":"322","author":"Kim","year":"2008","journal-title":"Science"},{"key":"172","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1002\/pros.22456","article-title":"The altered expression of MiR-221\/\u2212222 and MiR-23b\/\u221227b is associated with the development of human castration resistant prostate cancer","volume":"72","author":"Kantoff","year":"2012","journal-title":"Prostate"},{"key":"173","doi-asserted-by":"publisher","first-page":"1466","DOI":"10.1016\/j.juro.2011.11.082","article-title":"miR-21 as an independent biochemical recurrence predictor and potential therapeutic target for prostate cancer","volume":"187","author":"Shen","year":"2012","journal-title":"J Urol"},{"key":"174","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1002\/pros.21246","article-title":"Serum miRNA-21: elevated levels in patients with metastatic hormone-refractory prostate cancer and potential predictive factor for the efficacy of docetaxel-based chemotherapy","volume":"71","author":"Ye","year":"2011","journal-title":"Prostate"},{"key":"175","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4137\/CMO.S34534","article-title":"Resistance to Novel Antiandrogen Therapies in Metastatic Castration-Resistant Prostate Cancer","volume":"10","author":"Antonarakis","year":"2016","journal-title":"Clin Med Insights Oncol"},{"key":"176","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/0960-0760(92)90401-4","article-title":"The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens","volume":"41","author":"Mulder","year":"1992","journal-title":"J Steroid Biochem Mol Biol"},{"key":"177","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1158\/1078-0432.CCR-14-1220","article-title":"Abiraterone treatment in castration-resistant prostate cancer selects for progesterone responsive mutant androgen receptors","volume":"21","author":"Montgomery","year":"2015","journal-title":"Clin Cancer Res"},{"key":"178","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.1158\/2159-8290.CD-13-0226","article-title":"A clinically relevant androgen receptor mutation confers resistance to second-generation antiandrogens enzalutamide and ARN-509","volume":"3","author":"Hager","year":"2013","journal-title":"Cancer Discov"},{"key":"179","doi-asserted-by":"publisher","first-page":"e81","DOI":"10.1016\/S1470-2045(15)00620-8","article-title":"Precision oncology: origins, optimism, and potential","volume":"17","author":"Brada","year":"2016","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"180","doi-asserted-by":"publisher","first-page":"S11","DOI":"10.1016\/j.metabol.2012.08.016","article-title":"Personalized oncology: recent advances and future challenges","volume":"62","author":"Kalia","year":"2013","journal-title":"Metabolism"},{"key":"181","doi-asserted-by":"publisher","DOI":"10.1111\/bju.13522","article-title":"Getting Personal with Prostate Cancer: DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer","author":"Dasgupta","year":"2016","journal-title":"BJU Int"},{"key":"182","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.urology.2015.12.002","article-title":"Moving Beyond the Androgen Receptor in Advanced Prostate Cancer Commentary on: DNA-repair Defects and Olaparib in Metastatic Prostate Cancer","volume":"89","author":"Black","year":"2016","journal-title":"Urology"},{"key":"183","doi-asserted-by":"crossref","unstructured":"Olaparib Targets Some Advanced Prostate Cancers. Cancer Discov. 2016; 6:OF1. https:\/\/doi.org\/10.1158\/2159-8290.CD-NB2015-161.","DOI":"10.1158\/2159-8290.CD-NB2015-161"},{"key":"184","doi-asserted-by":"publisher","first-page":"52493","DOI":"10.18632\/oncotarget.9370","article-title":"Practical aspects of NGS-based pathways analysis for personalized cancer science and medicine","volume":"7","author":"Vinogradov","year":"2016","journal-title":"Oncotarget"},{"key":"185","doi-asserted-by":"publisher","first-page":"428","DOI":"10.3390\/diagnostics5040428","article-title":"When Prostate Cancer Circulates in the Bloodstream","volume":"5","author":"Vlaeminck-Guillem","year":"2015","journal-title":"Diagnostics (Basel)"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10901","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,12]],"date-time":"2020-05-12T07:23:31Z","timestamp":1589268211000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.10901"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,28]]},"references-count":185,"journal-issue":{"issue":"39","published-print":{"date-parts":[[2016,9,27]]}},"alternative-id":["10901","27487144"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.10901","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,28]]}}}